NetworkNewsBreaks – ArQule, Inc. (NASDAQ: ARQL) Closes $103.7M Follow-On
ArQule (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, recently closed its underwritten public offering of 10,637,500 shares of common stock, which includes 1,387,500 shares representing the over-allotment option that the underwriters fully exercised. With shares sold at the public offering price of $9.75 each, the offering resulted in gross proceeds of roughly $103.7 million. The company plans to use the proceeds toward its clinical programs and for general corporate purposes. ROTH Capital Partners acted as co-manager for the offering. To view the full press release, visit http://nnw.fm/kFr9H…







